Georg Schett

Author PubWeight™ 318.17‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The pathogenesis of rheumatoid arthritis. N Engl J Med 2011 12.16
2 Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007 8.47
3 Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007 7.29
4 Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012 4.31
5 Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010 4.01
6 Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007 3.02
7 Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008 2.97
8 Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med 2013 2.93
9 Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002 2.85
10 Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol 2010 2.70
11 Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis 2012 2.66
12 Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun 2012 2.65
13 Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012 2.59
14 Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum 2010 2.54
15 Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 2015 2.39
16 I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 2005 2.21
17 Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009 2.14
18 Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum 2007 2.12
19 Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004 2.08
20 Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta Diabetol 2014 2.07
21 Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2012 2.06
22 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity 2012 2.06
23 Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011 2.05
24 Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum 2009 2.04
25 Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A 2011 1.95
26 Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004 1.94
27 Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014 1.88
28 Detection of "Candidatus Neoehrlichia mikurensis" in two patients with severe febrile illnesses: evidence for a European sequence variant. J Clin Microbiol 2010 1.82
29 Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann Rheum Dis 2012 1.81
30 EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012 1.78
31 Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) 2011 1.74
32 Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002 1.72
33 Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum 2013 1.69
34 Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) 2011 1.68
35 Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010 1.67
36 PPARβ/δ governs Wnt signaling and bone turnover. Nat Med 2013 1.66
37 Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009 1.65
38 Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 2007 1.62
39 TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A 2007 1.61
40 Wnt inhibitory factor 1 deficiency uncouples cartilage and bone destruction in tumor necrosis factor α-mediated experimental arthritis. Arthritis Rheum 2013 1.59
41 Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis 2007 1.58
42 Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis 2012 1.58
43 The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis 2013 1.57
44 Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011 1.56
45 T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med 2014 1.56
46 Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 2004 1.53
47 Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (Oxford) 2010 1.53
48 Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. J Bone Miner Res 2012 1.49
49 Segmentation and quantification of bone erosions in high-resolution peripheral quantitative computed tomography datasets of the metacarpophalangeal joints of patients with rheumatoid arthritis. Rheumatology (Oxford) 2013 1.48
50 Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis. Arthritis Rheumatol 2014 1.48
51 Osteitis and synovitis, but not bone erosion, is associated with proteoglycan loss and microstructure damage in the cartilage of patients with rheumatoid arthritis. Ann Rheum Dis 2013 1.47
52 Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009 1.40
53 The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat Med 2005 1.39
54 Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012 1.37
55 Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009 1.36
56 Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 2013 1.36
57 The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006 1.34
58 Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008 1.33
59 Anaemia in inflammatory rheumatic diseases. Nat Rev Rheumatol 2012 1.33
60 Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014 1.27
61 The impact of coping strategies on mental and physical well-being in patients with rheumatoid arthritis. Semin Arthritis Rheum 2012 1.27
62 12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. J Immunol 2009 1.27
63 β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 2012 1.25
64 Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann Rheum Dis 2011 1.25
65 Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 2004 1.24
66 Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol 2005 1.24
67 Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 2007 1.23
68 Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 2007 1.23
69 Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities. Arthritis Res Ther 2011 1.22
70 High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 2011 1.21
71 Sodium overload and water influx activate the NALP3 inflammasome. J Biol Chem 2010 1.20
72 Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum 2006 1.20
73 Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008 1.20
74 Animal models for arthritis: innovative tools for prevention and treatment. Ann Rheum Dis 2011 1.20
75 Wif-1 is expressed at cartilage-mesenchyme interfaces and impedes Wnt3a-mediated inhibition of chondrogenesis. J Cell Sci 2009 1.19
76 Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep 2012 1.19
77 Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. Arthritis Rheum 2007 1.19
78 IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis 2011 1.18
79 Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006 1.17
80 Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 2003 1.17
81 Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. Autoimmun Rev 2010 1.17
82 Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010 1.16
83 Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008 1.16
84 Spondyloarthritis: may the force be with you? Ann Rheum Dis 2013 1.15
85 Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci 2005 1.15
86 Inflammatory monocytes and Fcγ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc Natl Acad Sci U S A 2013 1.14
87 Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 2008 1.14
88 Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum 2010 1.14
89 Autoimmunity's next top models. Nat Med 2012 1.14
90 The interaction of physical function and emotional well-being in rheumatoid arthritis--what is the impact on disease activity and coping? Semin Arthritis Rheum 2013 1.13
91 Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients. Semin Arthritis Rheum 2008 1.12
92 IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J Immunol 2011 1.12
93 RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 2005 1.11
94 CD44 is a determinant of inflammatory bone loss. J Exp Med 2005 1.10
95 Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation. J Bone Miner Res 2004 1.09
96 Monosodium urate crystals induce extracellular DNA traps in neutrophils, eosinophils, and basophils but not in mononuclear cells. Front Immunol 2012 1.09
97 WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J Bone Miner Res 2012 1.08
98 Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 2011 1.07
99 The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum 2008 1.06
100 Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther 2009 1.06
101 The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss. J Immunol 2009 1.06
102 Macrophages discriminate glycosylation patterns of apoptotic cell-derived microparticles. J Biol Chem 2011 1.05
103 Bonding the foe - NETting neutrophils immobilize the pro-inflammatory monosodium urate crystals. Front Immunol 2012 1.04
104 Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. FASEB J 2005 1.04
105 A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis 2010 1.04
106 R-spondin 1 protects against inflammatory bone damage during murine arthritis by modulating the Wnt pathway. Arthritis Rheum 2010 1.03
107 Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum 2010 1.03
108 Gadd45beta deficiency in rheumatoid arthritis: enhanced synovitis through JNK signaling. Arthritis Rheum 2009 1.02
109 The rs1143679 (R77H) lupus associated variant of ITGAM (CD11b) impairs complement receptor 3 mediated functions in human monocytes. Ann Rheum Dis 2012 1.02
110 RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther 2009 1.02
111 Association of serum-soluble heat shock protein 60 with carotid atherosclerosis: clinical significance determined in a follow-up study. Stroke 2005 1.02
112 Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res 2011 1.02
113 Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009 1.02
114 IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol 2012 1.01
115 Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. Arthritis Res Ther 2005 1.01
116 Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis. Autoimmunity 2009 1.01
117 A detailed comparative study of high-resolution ultrasound and micro-computed tomography for detection of arthritic bone erosions. Arthritis Rheum 2011 1.01
118 Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum 2008 1.00
119 Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011 1.00
120 Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int 2011 1.00
121 JNK1 is not essential for TNF-mediated joint disease. Arthritis Res Ther 2004 0.99
122 Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression. J Immunol 2009 0.99
123 Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis 2013 0.99
124 Elevated Fra-1 expression causes severe lipodystrophy. J Cell Sci 2011 0.99
125 High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice. Eur J Immunol 2011 0.98
126 The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis 2012 0.98
127 Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum 2012 0.96
128 Combining functional magnetic resonance imaging with mouse genomics: new options in pain research. Neuroreport 2010 0.96
129 Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013 0.96
130 Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study. Ann Rheum Dis 2012 0.96
131 CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum 2010 0.95
132 B-cell infiltrates induce endosteal bone formation in inflammatory arthritis. J Bone Miner Res 2008 0.95
133 The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death. Innate Immun 2012 0.95
134 Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 2012 0.95
135 Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. J Cell Mol Med 2011 0.95
136 Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases. Arthritis Rheum 2009 0.95
137 The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009 0.95
138 CRP/anti-CRP antibodies assembly on the surfaces of cell remnants switches their phagocytic clearance toward inflammation. Front Immunol 2011 0.95
139 Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011 0.94
140 Redox modulation of HMGB1-related signaling. Antioxid Redox Signal 2013 0.94
141 The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2010 0.94
142 TNF and bone. Curr Dir Autoimmun 2010 0.93
143 Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis Rheum 2010 0.93
144 Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012 0.93
145 Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011 0.93
146 Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. Neoplasia 2010 0.92
147 Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann Rheum Dis 2013 0.92
148 Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance. Eur J Immunol 2011 0.92
149 Vitamin D receptor regulates TNF-mediated arthritis. Ann Rheum Dis 2011 0.91
150 The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis. J Immunol 2007 0.91
151 Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis 2010 0.91
152 Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin Rev Allergy Immunol 2005 0.90
153 NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseases. Proc Natl Acad Sci U S A 2013 0.90
154 Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum 2008 0.90
155 IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum 2012 0.90
156 Moonlighting osteoclasts as undertakers of apoptotic cells. Autoimmunity 2012 0.90
157 Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. Ann Rheum Dis 2012 0.90
158 Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel targets in bone and cartilage. Best Pract Res Clin Rheumatol 2010 0.89
159 Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis 2012 0.89
160 Serum Dkk-1 levels of DISH patients are not different from healthy controls. Joint Bone Spine 2011 0.89
161 The lonely death: chondrocyte apoptosis in TNF-induced arthritis. Autoimmunity 2007 0.89
162 Successful remission induction with a combination therapy of rituximab, cyclophosphamide, and steroids in a patient with refractory optic neuritis in Wegener's granulomatosis. Clin Rheumatol 2010 0.88
163 The uptake by blood-borne phagocytes of monosodium urate is dependent on heat-labile serum factor(s) and divalent cations. Autoimmunity 2010 0.88
164 Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus. Arthritis Rheum 2013 0.88
165 Inflammation and destruction of the joints--the Wnt pathway. Joint Bone Spine 2008 0.88
166 Decreased quantity and quality of the periarticular and nonperiarticular bone in patients with rheumatoid arthritis: a cross-sectional HR-pQCT study. J Bone Miner Res 2014 0.88
167 Osteoblast-specific expression of Fra-2/AP-1 controls adiponectin and osteocalcin expression and affects metabolism. J Cell Sci 2013 0.88
168 Overexpression of tumor necrosis factor causes bilateral sacroiliitis. Arthritis Rheum 2004 0.88
169 The structural basis of MRI bone erosions: an assessment by microCT. Ann Rheum Dis 2012 0.87
170 Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis Rheum 2012 0.87
171 Pathogenesis of Churg-Strauss syndrome: recent insights. Autoimmunity 2009 0.87
172 Arthritis and bone loss: a hen and egg story. Curr Opin Rheumatol 2014 0.87
173 Cell-intrinsic NF-κB activation is critical for the development of natural regulatory T cells in mice. PLoS One 2011 0.87
174 Phospholipase Cγ2 is required for basal but not oestrogen deficiency-induced bone resorption. Eur J Clin Invest 2011 0.87
175 Pathophysiology of spondyloarthritis. Curr Rheumatol Rep 2011 0.86
176 Detection and chromatographic removal of lipopolysaccharide in preparations of multifunctional galectins. Biochem Biophys Res Commun 2008 0.86
177 Sodium and potassium urate crystals differ in their inflammatory potential. Autoimmunity 2009 0.86
178 A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF. Hum Mol Genet 2011 0.86
179 Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis 2012 0.85
180 Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012 0.85
181 Imbalance of local bone metabolism in inflammatory arthritis and its reversal upon tumor necrosis factor blockade: direct analysis of bone turnover in murine arthritis. Arthritis Res Ther 2006 0.85
182 Inhibition of sumoylation prevents experimental fibrosis. Ann Rheum Dis 2012 0.85
183 The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011 0.85
184 The Wnt antagonist Wif-1 interacts with CTGF and inhibits CTGF activity. J Cell Physiol 2012 0.85
185 B cells are critical for autoimmune pathology in Scurfy mice. Proc Natl Acad Sci U S A 2013 0.85
186 MoMa from patients with systemic lupus erythematosus show altered adhesive activity. Autoimmunity 2009 0.85
187 Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum 2010 0.85
188 Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis 2010 0.84
189 Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Ann Rheum Dis 2011 0.84
190 Synovial immunopathology in haemochromatosis arthropathy. Ann Rheum Dis 2009 0.84
191 PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis. FASEB J 2009 0.84
192 Pathophysiology of new bone formation and ankylosis in spondyloarthritis. Rheum Dis Clin North Am 2012 0.84
193 UVB-irradiated apoptotic cells induce accelerated growth of co-implanted viable tumor cells in immune competent mice. Autoimmunity 2013 0.84
194 Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis. Arthritis Rheum 2013 0.84
195 Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors. Ann Rheum Dis 2012 0.83
196 Treatment with DNAse I fosters binding to nec PBMC of CRP. Autoimmunity 2009 0.83
197 Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 2012 0.83
198 Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo. J Cell Mol Med 2009 0.83
199 Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum 2010 0.83
200 T cells as key players for bone destruction in gouty arthritis? Arthritis Res Ther 2011 0.83
201 The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. Ann Rheum Dis 2012 0.83
202 Prevalence of paraneoplastic rheumatic syndromes and their antibody profile among patients with solid tumours. Clin Rheumatol 2011 0.83
203 RSK2 protects mice against TNF-induced bone loss. J Cell Sci 2012 0.83
204 Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Ann Rheum Dis 2012 0.83
205 12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function. J Clin Invest 2015 0.83
206 Ucma is not necessary for normal development of the mouse skeleton. Bone 2011 0.82
207 Standardization of joint examination technique leads to a significant decrease in variability among different examiners. J Rheumatol 2010 0.82
208 Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study. J Rheumatol 2013 0.82
209 Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. Glycobiology 2012 0.82
210 Inflammatory bone spur formation in psoriatic arthritis is different from bone spur formation in hand osteoarthritis. Arthritis Rheumatol 2014 0.82
211 Differentially regulated expression of growth differentiation factor 5 and bone morphogenetic protein 7 in articular cartilage and synovium in murine chronic arthritis: potential importance for cartilage breakdown and synovial hypertrophy. Arthritis Rheum 2008 0.82
212 Bone histomorphometry in arthritis models. Methods Mol Med 2007 0.81
213 Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice. Arthritis Rheum 2008 0.81
214 Differences in the patient's and the physician's perspective of disease in psoriatic arthritis. Semin Arthritis Rheum 2012 0.81
215 Catabolic and anabolic periarticular bone changes in patients with rheumatoid arthritis: a computed tomography study on the role of age, disease duration and bone markers. Arthritis Res Ther 2013 0.81
216 Induction of apoptosis in circulating angiogenic cells by microparticles. Arthritis Rheum 2011 0.81
217 Osteoclasts and Arthritis. J Bone Miner Res 2009 0.81
218 Polymorphisms in the Hsp70 gene locus are genetically associated with systemic lupus erythematosus. Ann Rheum Dis 2010 0.81
219 The nuclear receptor Nr4a1 mediates anti-inflammatory effects of apoptotic cells. J Immunol 2014 0.81
220 Transcription factor Fra-1 induces cholangitis and liver fibrosis. Hepatology 2011 0.81
221 The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis. Arthritis Rheumatol 2014 0.80
222 How neutrophil extracellular traps orchestrate the local immune response in gout. J Mol Med (Berl) 2015 0.80
223 ACPA and bone loss in rheumatoid arthritis. Curr Rheumatol Rep 2013 0.80
224 Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis. Ann Rheum Dis 2013 0.80
225 The 12/15-lipoxygenase pathway promotes osteoclast development and differentiation. Autoimmunity 2009 0.80
226 IgG opsonized nuclear remnants from dead cells cause systemic inflammation in SLE. Autoimmunity 2010 0.80
227 Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover. J Bone Miner Res 2013 0.80
228 Role of NOD1 polymorphism in susceptibility and clinical progression of rheumatoid arthritis. Rheumatology (Oxford) 2013 0.80
229 Autoantibody-mediated bone loss. Curr Osteoporos Rep 2014 0.80
230 Idiopathic hand osteoarthritis vs haemochromatosis arthropathy--a clinical, functional and radiographic study. Rheumatology (Oxford) 2013 0.80
231 Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. Arthritis Rheum 2008 0.80
232 Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. Arthritis Rheum 2011 0.79
233 JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis Rheum 2012 0.79
234 Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers. Arthritis Rheum 2010 0.79
235 Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 2012 0.79
236 Running has a negative effect on bone metabolism and proinflammatory status in male aged rats. Exp Gerontol 2008 0.79
237 Hereditary hemochromatosis as a risk factor for joint replacement surgery. Am J Med 2010 0.79
238 Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. Ann Rheum Dis 2013 0.79
239 Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Ann Rheum Dis 2014 0.79
240 Clinical Images: Hippokrates confirmed by positron emission tomography. Arthritis Rheum 2011 0.78
241 Anti-tumour necrosis factor alpha therapy in patients with impaired renal function. Ann Rheum Dis 2007 0.78
242 Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood 2012 0.78
243 Detection of low level cryoglobulins by flow cytometry. Cytometry A 2012 0.78
244 Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1. Ann Rheum Dis 2012 0.78
245 Bone research in 2012: the ups and downs of bone in health and rheumatic disease. Nat Rev Rheumatol 2013 0.78
246 Risk prediction for severe osteoarthritis. Ann Rheum Dis 2010 0.78
247 The binding of sera of patients with SLE to bacterial and mammalian DNA. Clin Immunol 2005 0.78
248 Definition for Rheumatoid Arthritis Erosions Imaged with High Resolution Peripheral Quantitative Computed Tomography and Interreader Reliability for Detection and Measurement. J Rheumatol 2016 0.78
249 Aberrant expression of the autoantigen heterogeneous nuclear ribonucleoprotein-A2 (RA33) and spontaneous formation of rheumatoid arthritis-associated anti-RA33 autoantibodies in TNF-alpha transgenic mice. J Immunol 2005 0.78
250 VCAM-1 serum levels are associated with arthropathy in hereditary haemochromatosis. Ann Rheum Dis 2013 0.77
251 Entheses and bones in spondyloarthritis: 2008 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). J Rheumatol 2009 0.77
252 Premature osteoarthritis as presenting sign of type II collagenopathy: a case report and literature review. Semin Arthritis Rheum 2012 0.77
253 Registration of 2D histological sections with 3D micro-CT datasets from small animal vertebrae and tibiae. Comput Methods Biomech Biomed Engin 2014 0.77
254 Activation of pregnane X receptor inhibits experimental dermal fibrosis. Ann Rheum Dis 2013 0.77
255 Influence of antiTNF-alpha antibody treatment on fracture healing under chronic inflammation. BMC Musculoskelet Disord 2014 0.77
256 Characterization and quantification of angiogenesis in rheumatoid arthritis in a mouse model using μCT. BMC Musculoskelet Disord 2014 0.77
257 Cortical remodeling during menopause, rheumatoid arthritis, glucocorticoid and bisphosphonate therapy. Arthritis Res Ther 2013 0.77
258 Inflammation-associated changes in bone homeostasis. Inflamm Allergy Drug Targets 2012 0.77
259 Updating the OMERACT filter: implications for imaging and soluble biomarkers. J Rheumatol 2014 0.77
260 Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. Am J Pathol 2012 0.77
261 Anti–citrullinated protein antibody positivity correlates with cartilage damage and proteoglycan levels in patients with rheumatoid arthritis in the hand joints. Arthritis Rheumatol 2014 0.77
262 Do low vitamin D levels cause problems of waste removal in patients with SLE? Rheumatology (Oxford) 2011 0.76
263 Increased expression of CD154 and FAS in SLE patients' lymphocytes. Rheumatol Int 2009 0.76
264 The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib. J Immunol 2010 0.76
265 Coping strategies and depressiveness in primary systemic vasculitis--what is their impact on health-related quality of life? Rheumatology (Oxford) 2013 0.76
266 Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele. Autoimmunity 2012 0.75
267 Deletion of the receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia and bone damage in arthritis. Ann Rheum Dis 2013 0.75
268 Denosumab, osteoporosis, and prevention of fractures. N Engl J Med 2009 0.75
269 The mitogen-activated protein kinase p38α regulates tubular damage in murine anti-glomerular basement membrane nephritis. PLoS One 2013 0.75
270 A typically atypical tenosynovitis. Clin Rheumatol 2010 0.75
271 A case report of plasma exchange, steroids, mycophenolate mofetil and cyclophosphamide in acquired factor VIII inhibitors. Ther Apher Dial 2008 0.75
272 Cardiomyopathy in murine models of systemic sclerosis. Arthritis Rheumatol 2015 0.75
273 Binary segmentation masks can improve intrasubject registration accuracy of bone structures in CT images. Ann Biomed Eng 2010 0.75
274 Strawberry gingivitis. Joint Bone Spine 2012 0.75
275 Can ANCA differentiate eosinophilic granulomatosis with polyangiitis (Churg-Strauss) from idiopathic hypereosinophilic syndrome? Clin Exp Rheumatol 2013 0.75
276 Sudden visual loss in a patient with microscopic polyangiitis. Rheumatology (Oxford) 2009 0.75
277 Parathyroid Hormone is Related to Dysplasia and a Higher Rate of Distal Colorectal Adenoma in Women but Not Men. Horm Cancer 2015 0.75
278 Gout mimicking rheumatoid arthritis. Semin Arthritis Rheum 2016 0.75
279 Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody. Ther Apher Dial 2008 0.75
280 Rheumatoid arthritis and multiple sclerosis: direful siblings, different strategies. FEBS Lett 2011 0.75
281 Experimental lupus is aggravated in mouse strains with impaired induction of neutrophil extracellular traps. JCI Insight 2017 0.75
282 The emergence of antineutrophil cytoplasmic antibodies may precede the clinical onset of Churg-Strauss syndrome. Arthritis Rheum 2009 0.75
283 Validation of a radiographic scoring system for haemochromatosis arthropathy. Ann Rheum Dis 2010 0.75
284 Erratum: Reply to "Neutrophils are not required for resolution of acute gouty arthritis in mice". Nat Med 2017 0.75
285 Clinical images: rheumatologic irony. Arthritis Rheum 2007 0.75